Coeptis Therapeutics (NASDAQ:ZSQR) Shares Down 2.9% - Time to Sell?

Key Points

• Coeptis Therapeutics shares fell 2.9% to about $3.00, trading well below their 50-day and 200-day moving averages of $4.97 and $9.58, respectively.
• Analyst sentiment is firmly negative: Weiss Ratings downgraded the stock to “sell,” Wall Street Zen also issued a “sell” rating, and MarketBeat reports an average rating of “Sell.”
• The company reported a quarterly loss of $0.28 per share on $1.58 million in revenue, alongside a negative 773.72% net margin and negative 49.45% return on equity, highlighting significant financial weakness.

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR - Get Free Report) dropped 2.9% on Wednesday . The stock traded as low as $2.97 and last traded at $3.00. 221,953 shares traded hands during mid-day trading, a decline of 31% from the average session volume of 320,146 shares. The stock had previously closed at $3.09.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Weiss Ratings cut shares of Coeptis Therapeutics from a "sell (d-)" rating to a "sell (e-)" rating in a research report on Friday, August 14th. Wall Street Zen cut shares of Coeptis Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 13th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of "Sell".

Coeptis Therapeutics Stock Down 2.9%

The firm's fifty day moving average price is $4.97 and its two-hundred day moving average price is $9.58. The stock has a market capitalization of $159 million, a PE ratio of -1.84 and a beta of -0.25.

Coeptis Therapeutics (NASDAQ:ZSQR - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter. The firm had revenue of $1.58 million during the quarter. Coeptis Therapeutics had a negative return on equity of 49.45% and a negative net margin of 773.72%.

Institutional Trading of Coeptis Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of ZSQR. Geode Capital Management LLC boosted its position in shares of Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company's stock worth $600,000 after acquiring an additional 4,721 shares during the last quarter. State Street Corp increased its holdings in Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company's stock valued at $382,000 after acquiring an additional 6,962 shares during the last quarter. Marshall Wace LLP purchased a new stake in Coeptis Therapeutics in the 4th quarter worth $259,000. Finally, Steward Partners Investment Advisory LLC lifted its stake in Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company's stock worth $71,000 after purchasing an additional 2,500 shares in the last quarter. 13.88% of the stock is owned by hedge funds and other institutional investors.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.